Scottish Medicines Consortium
Providing advice about the status of all newly licensed medicines
www.scottishmedicines.org.uk
Delta House 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Professor Angela Timoney FRPharmS
NHS SCOTLAND

Product Update:

bimatoprost 0.3mg/mL single-dose eye drops (Lumigan UD®)

(No: 839/13)

Allergan Ltd

11 January 2013 *(Issued 08 February 2013)*

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

bimatoprost 0.3mg/mL preservative-free eye drops (Lumigan UD®) are accepted for restricted use within NHS Scotland.

Indication under review: reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).

SMC restriction: to use in patients who have proven sensitivity to the preservative benzalkonium chloride.

SMC has previously accepted preserved bimatoprost eye-drops for use in NHS Scotland. This preparation is substantially more expensive than the equivalent multi-dose eye drop preparation with preservative.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 30 January 2013.

Chairman
Scottish Medicines Consortium

Published 11 March 2013